Supplementary Figure S4 from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer

Nicolas Sayegh; Ryon P. Graf; Umang Swami; Zeynep İrem Özay; Chadi Hage Chehade; Julia Andrea Elvin; Douglas I. Lin; Júlia C.F. Quintanilha; Gerald Li; Alan Haruo Bryce; Rana R. McKay; Jeffrey S. Ross; Tian Zhang; Neeraj Agarwal

doi:10.1158/1078-0432.31353274

Supplementary Figure S4 from Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer

2026 Open access

Read full text

Authors: Nicolas Sayegh, Ryon P. Graf, Umang Swami, Zeynep İrem Özay, Chadi Hage Chehade, Julia Andrea Elvin, Douglas I. Lin, Júlia C.F. Quintanilha, Gerald Li, Alan Haruo Bryce, Rana R. McKay, Jeffrey S. Ross

+2 more

Tian Zhang, Neeraj Agarwal

DOI: 10.1158/1078-0432.31353274

Cited by: 0

Abstract

Sensitivity analysis: non-MSI-H comparison. (A) Standardized mean difference is shown for features pre- and post- adjustment for the TMB10+ cohort. Propensity-adjusted comparison of ICI (tTMB≥10) vs. taxanes (any tTMB level) is shown for (B) TTNT and (C) OS among the cohort excluding MSI-H.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Prostate Cancer Treatment and Research PARP inhibition in cancer therapy

Publication details

Publication date: 17 February 2026
Language: EN